Related Experiment Video
Updated: May 27, 2026
06:23
Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
Published on: January 17, 2025
Blood glutathione decrease in subjects carrying lamin A/C gene mutations is an early marker of cardiac involvement
Christophe Meune1, Lara Khouzami, Karim Wahbi
1Université Paris Descartes, AP-HP, Département de Cardiologie, Groupe Hospitalier Cochin, F-75014, France.
Neuromuscular Disorders : NMD
|November 11, 2011
Summary
Blood glutathione levels can help detect early cardiac dysfunction in Emery-Dreifuss muscular dystrophy patients with LMNA gene mutations. This biomarker may identify reduced ventricular contractility before significant changes in ejection fraction occur.
Area of Science:
- Cardiology
- Genetics
- Biochemistry
Background:
- Dominant inherited Emery-Dreifuss muscular dystrophy (EDMD) and limb-girdle muscular dystrophy type 1B (LGMD1B) are linked to LMNA gene mutations.
- These conditions often present with life-threatening cardiac disease, yet reliable early diagnostic biomarkers are lacking.
- Glutathione depletion is observed in non-genetic cardiac diseases, suggesting a potential role in cardiac health.
Purpose of the Study:
- To investigate blood glutathione levels as a potential biomarker for early cardiac dysfunction in LMNA-mutated patients.
- To assess the correlation between blood glutathione and left/right ventricular (LV/RV) contractility.
- To determine if blood glutathione can reliably detect reduced contractility in patients with preserved ejection fraction.
Main Methods:
- Examined blood glutathione levels in 22 LMNA-mutated subjects with preserved LVEF (>40%).
- Evaluated LV/RV contractility using echocardiography with tissue-Doppler imaging.
- Correlated blood glutathione levels with cardiac contractility and used ROC analysis to assess diagnostic accuracy.
Main Results:
- Blood glutathione levels positively correlated with LV and RV contractility (p<0.05).
- Subjects with reduced LV/RV contractility showed a 23% decrease in blood glutathione compared to those with normal contractility.
- ROC analysis indicated blood glutathione reliably detects reduced LV/RV contractility (AUC: 0.90, p=0.01).
Conclusions:
- Decreased blood glutathione may serve as an early indicator of reduced ventricular contractility in LMNA-mutated muscular dystrophy patients.
- This biomarker could aid in the early detection of cardiac involvement before significant changes in LVEF.
- Blood glutathione offers a promising, non-invasive tool for monitoring cardiac health in this patient population.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...